viernes, 4 de agosto de 2017

12 REFERENCIAS BIBLIOGRÁFICAS ALQUINOS


  1. Adler, R. (2006). Clair Patterson’s Battle Against Lead Pollution. California Institute Of Technology Pasadena, California.
  2. Aminov, R. I. (2010). A brief history of the antibiotic era: lessons learned and challenges for the future. Frontiers in Microbiology, 1.
  3. Anastas, P. T., & Kirchhoff, M. M. (2002). Origins, current status, and future challenges of green chemistry. Accounts of Chemical Research, 35(9), 686–694.
  4. Årdal, C., Alstadsæter, A., & Røttingen, J.-A. (2011). Common characteristics of open source software development and applicability for drug discovery: a systematic review. Health Research Policy and Systems, 9(1), 36.
  5. Arlington, S. (2012). From Vision to Decision: Pharma 2020. Pharma2020. PricewaterhouseCoopers. Http://www. Pwc. Com/gx/en/industries/pharmaceuticals-Lifesciences/pharma-2020/industry-Strategies-Trends-Analysis. Html.
  6. Arrowsmith, J., & Miller, P. (2013). Trial watch: phase II and phase III attrition rates 2011-2012. Nature Reviews Drug Discovery, 12(8), 569.
  7. Austin, D. H. (2006). Research and development in the pharmaceutical industry. Congress of the United States, Congressional Budget Office.
  8. Barton, J. H., & Emanuel, E. J. (2005). The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA, 294(16), 2075–2082.
  9. Bauchner, H., & Fontanarosa, P. B. (2013). Restoring confidence in the pharmaceutical industry. Jama, 309(6), 607–609.
  10. Benfey, O. T., & Morris, P. J. T. (2001). Robert Burns Woodward: Architect and Artist in the World of Molecules. Chemical Heritage Foundation.
  11. Bergmann, L., Berns, B., Dalgleish, A. G., von Euler, M., Hecht, T. T., Lappin, G. L., … Embacher-Aichorn, S. (2010). Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Annals of Oncology, 21(8), 1573–1578.
  12. Boguski, M. S., Mandl, K. D., & Sukhatme, V. P. (2009). Repurposing with a difference. Science, 324(5933), 1394–1395.
  13. Boldrin, M. (2009). Against intellectual monopoly. Syracuse Sci. & Tech. L. Rep., 2009, 130.
  14. Boon, W. P. C., Moors, E. H. M., Meijer, A., & Schellekens, H. (2010). Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clinical Pharmacology & Therapeutics, 88(6), 848–853.
  15. Boppre, M. (2011). The ecological context of pyrrolizidine alkaloids in food, feed and forage: an overview. Food Additives & Contaminants: Part A, 28(3), 260–281.
  16. Breckenridge, A. (2010). Regulatory challenges, reimbursement, and risk–benefit assessment. Clinical Pharmacology & Therapeutics, 88(2), 153–154.
  17. Breckenridge, A., Feldschreiber, P., Gregor, S., Raine, J., & Mulcahy, L.-A. (2011). Evolution of regulatory frameworks. Nature Reviews. Drug Discovery, 10(1), 3.
  18. Brock, W. H. (1985). Chemical atomism in the nineteenth century: from Dalton to Cannizzaro.
  19. Brown, W. H., Iverson, B. L., Anslyn, E. V, Foote, C. S., & Novak, B. M. (2018). Organic Chemistry (8th ed.). Cengage Learning.
  20. Brown, W. H., & Poon, T. (2014). Introduction to Organic Chemistry (5th ed.). Wiley & Sons.
  21. Bruice, P. Y. (2011). Organic Chemistry (8th ed.). Boston: Prentice Hall.
  22. Bruice, P. Y. (2014a). Essential Organic Chemistry (2nd ed.). Pearson.
  23. Bruice, P. Y. (2014b). Organic Chemistry (7th ed.). Pearson.
  24. Bruice, P. Y. (2016). Organic Chemistry (8th ed.). Pearson.
  25. Carey, F. A., & Giuliano, R. M. (2011). Organic Chemistry (8th ed.). McGraw-Hill New York.
  26. Carson, R. (1962). Silent spring ((2002) ed.). (Houghton Mifflin Harcourt), Mariner Books, 1962.
  27. Chain, E., Florey, H. W., Gardner, A. D., Heatley, N. G., Jennings, M. A., Orr-Ewing, J., … Peltier, L. F. (2005). THE CLASSIC: Penicillin as a Chemotherapeutic Agent. Clinical Orthopaedics and Related Research, 439, 23–26.
  28. Cheeke, P. R. (1989). Toxicants of plant origin: alkaloids (Vol. 1). CRC Press.
  29. Chigwedere, P., & Essex, M. (2010). AIDS denialism and public health practice. AIDS and Behavior, 14(2), 237–247.
  30. Chopra, I., Hesse, L., & O’Neill, A. (2002). Discovery and development of new anti-bacterial drugs. Pharmacochemistry Library, 32, 213–225.
  31. Clayden, J., Greeves, N., & Warren, S. (2012). Organic Chemistry (2nd ed.). Oxford University Press.
  32. Clement, M. E., Okeke, N. L., & Hicks, C. B. (2014). Treatment of syphilis: a systematic review. Jama, 312(18), 1905–1917.
  33. Cohen, J. T., Neumann, P. J., & Weinstein, M. C. (2008). Does preventive care save money? Health economics and the presidential candidates. N Engl J Med, 2008(358), 661–663.
  34. Comanor, W. S. (1964). Research and competitive product differentiation in the pharmaceutical industry in the United States. Economica, 31(124), 372–384.
  35. Commission, F. T., & Commission, F. T. (1958). Economic report on antibiotics manufacture. United States Government Printing Office: Washington, DC.
  36. Competition, D. G. (2009). Pharmaceutical Sector Inquiry Final Report’. Brussels: European Commission.
  37. Corey, E. J. (1989). The logic of chemical synthesis. Рипол Классик.
  38. Corey, E. J. (2012). Molecules and medicine. John Wiley & Sons.
  39. Corey, E. J., & Kurti, L. (2013). Enantioselective Chemical Synthesis: Methods, Logic, and Practice. Elsevier.
  40. Crawford, M. J. (2014). An Empire’s Extract: Chemical Manipulations of Cinchona Bark in the Eighteenth-Century Spanish Atlantic World. Osiris, 29(1), 215–229.
  41. Cuatrecasas, P. (2006). Drug discovery in jeopardy. Journal of Clinical Investigation, 116(11), 2837.
  42. DiMasi, J. A., & Grabowski, H. G. (2007). Should the patent system for new medicines be abolished? Clinical Pharmacology & Therapeutics, 82(5), 488–490.
  43. DiMasi, J. A., & Paquette, C. (2005). The economics of follow-on drug research and development: Trends in entry rates and the timing of development—The authors’ reply. Pharmacoeconomics, 23(12), 1193–1202.
  44. Domagk, G. (1935). Ein beitrag zur chemotherapie der bakteriellen infektionen. DMW-Deutsche Medizinische Wochenschrift, 61(07), 250–253.
  45. Donohue, J. M., Cevasco, M., & Rosenthal, M. B. (2007). A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med, 2007(357), 673–681.
  46. Dufty, N. E., & Leverton, D. (2014). The treatment of syphilis with salvarsan. Journal of the Royal Army Medical Corps, 160, i21.
  47. Ebbers, H. C., Mantel-Teeuwisse, A. K., Moors, E. H. M., Schellekens, H., & Leufkens, H. G. (2011). Today’s Challenges in Pharmacovigilance. Drug Safety, 34(4), 273–287.
  48. Ebbers, H. C., Pieters, T., Leufkens, H. G., & Schellekens, H. (2012). Effective pharmaceutical regulation needs alignment with doctors. Drug Discovery Today, 17(3), 100–103.
  49. Eichler, H.-G., Abadie, E., Raine, J. M., & Salmonson, T. (2009). Safe drugs and the cost of good intentions. New England Journal of Medicine, 360(14), 1378–1380.
  50. Emmerich, R., & Löw, O. (1899). Bakteriolytische Enzyme als Ursache der erworbenen Immunität und die Heilung von Infectionskrankheiten durch dieselben. Zeitschrift Für Hygiene Und Infektionskrankheiten, 31(1), 1–65.
  51. Enne, V. I., Bennett, P. M., Livermore, D. M., & Hall, L. M. C. (2004). Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. Journal of Antimicrobial Chemotherapy, 53(6), 958–963.
  52. Eschenmoser, A. (2011). Etiology of potentially primordial biomolecular structures: from vitamin B12 to the nucleic acids and an inquiry into the chemistry of life’s origin: a retrospective. Angewandte Chemie International Edition, 50(52), 12412–12472.
  53. Favre, H. A., & Powell, W. H. (2013). Nomenclature of organic chemistry: IUPAC recommendations and preferred names 2013. Royal Society of Chemistry.
  54. FitzGerald, G. A. (2008). Drugs, industry, and academia. Science, 320(5883), 1563.
  55. FitzGerald, G. A. (2010). Perestroika in pharma: evolution or revolution in drug development? Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 77(4), 327–332.
  56. Fleming, A. (1929). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. British Journal of Experimental Pathology, 10(3), 226.
  57. Forda, S. R., Bergström, R., Chlebus, M., Barker, R., & Andersen, P. H. (2013). Priorities for improving drug research, development and regulation. Nature Reviews. Drug Discovery, 12(4), 247.
  58. Fowler, M. E. (1983). Plant poisoning in free-living wild animals: a review. Journal of Wildlife Diseases, 19(1), 34–43.
  59. Frangioni, J. V. (2008). The impact of greed on academic medicine and patient care. Nature Biotechnology, 26(5), 503–507.
  60. Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., & Thompson, L. J. (1999). The safety of newly approved medicines: do recent market removals mean there is a problem? Jama, 281(18), 1728–1734.
  61. Gabriel, J. M. (2009). A thing patented is a thing divulged: Francis E. Stewart, George S. Davis, and the legitimization of intellectual property rights in pharmaceutical manufacturing, 1879–1911. Journal of the History of Medicine and Allied Sciences, 64(2), 135–172.
  62. Garber, A. M. (2009). An uncertain future for cardiovascular drug development?
  63. Garnier, J.-P. (2008). Rebuilding the R&D engine in big pharma. Harvard Business Review, 86(5), 68–70.
  64. Glausiusz, J. (2007). Better planet: can a maligned pesticide save lives. Discover Magazine, 20.
  65. Gold, E. R., Kaplan, W., Orbinski, J., Harland-Logan, S., & Sevil, N. (2010). Are patents impeding medical care and innovation? PLoS Medicine, 7(1), e1000208.
  66. Gøtzsche, P. C. (2013). Developing a new drug costs less than $100 m, not $900 m. BMJ, 346, f398.
  67. Grody, W. W., & Getzug, T. (2010). Colchicine’s other indication—effect of FDA action. New England Journal of Medicine, 363(23), 2267–2268.
  68. Grootendorst, P., Hollis, A., Levine, D. K., Pogge, T., & Edwards, A. M. (2011). New approaches to rewarding pharmaceutical innovation. Canadian Medical Association Journal, 183(6), 681–685.
  69. Gunja, N., & Brown, J. A. (2012). Energy drinks: health risks and toxicity. Med J Aust, 196(1), 46–49.
  70. Hawtorn, F. (2005). The Merck Druggernaut: The Inside Story of a Pharmaceutical Giant. Wiley.
  71. Hays, E. E., Wells, I. C., Katzman, P. A., Cain, C. K., Jacobs, F. A., Thayer, S. A., … Muir, R. D. (1945). Antibiotic Substances produced by Pseu-domonas aeruginosa. Biological Chemistry, 159(3), 725–750.
  72. Heemstra, H. E., de Vrueh, R. L. A., van Weely, S., Büller, H. A., & Leufkens, H. G. M. (2008). Orphan drug development across Europe: bottlenecks and opportunities. Drug Discovery Today, 13(15), 670–676.
  73. Higgins, M. J., & Graham, S. J. H. (2009). Balancing innovation and access: patent challenges tip the scales. Science, 326(5951), 370–371.
  74. Hill, C. W. L., & Hansen, G. S. (1991). A longitudinal study of the cause and consequences of changes in diversification in the US pharmaceutical industry 1977–1986. Strategic Management Journal, 12(3), 187–199.
  75. Hogerzeil, H. V. (2013). Big Pharma and social responsibility--the Access to Medicine Index. The New England Journal of Medicine, 369(10), 896.
  76. Hopkins, M. M., Crane, P. A., Nightingale, P., & Baden-Fuller, C. (2013). Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980–2009. Industrial and Corporate Change, 22(4), 903–952.
  77. Hrin, T. N., Milenković, D. D., & Segedinac, M. D. (2016). The Effect of Systemic Synthesis Questions [SSynQs] on Students’ Performance and Meaningful Learning in Secondary Organic Chemistry Teaching. International Journal of Science and Mathematics Education, 14(5), 805–824.
  78. Kaitin, K. I. (2010). Deconstructing the drug development process: the new face of innovation. Clinical Pharmacology & Therapeutics, 87(3), 356–361.
  79. Kaplan, W., Wirtz, V., Mantel, A., & Béatrice, P. S. U. U. (2013). Priority Medicines for Europe and the World Update 2013 report. Methodology, 2, 7.
  80. Kaufmann, G. F., Sartorio, R., Lee, S.-H., Rogers, C. J., Meijler, M. M., Moss, J. A., … Janda, K. D. (2005). Revisiting quorum sensing: discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proceedings of the National Academy of Sciences of the United States of America, 102(2), 309–314.
  81. Kesselheim, A. S. (2007). Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system. The AAPS Journal, 9(3), E306–E311.
  82. Kesselheim, A. S. (2011). An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. The Milbank Quarterly, 89(3), 450–502.
  83. Kielstra, P. (2012). Reinventing biopharma: strategies for an evolving marketplace. The value challenge. Economist Intelligence Unit Limited.
  84. Kitsis, E. A. (2009). Rx for the pharmaceutical industry: call your doctors. Hastings Center Report, 39(4), 18–21.
  85. Klein, D. (2015). Organic Chemistry (2nd ed.). Wiley.
  86. Knowles, S. M. (2010). Fixing the legal framework for pharmaceutical research. Science, 327(5969), 1083–1084.
  87. Kolman, C. J., Centurion-Lara, A., Lukehart, S. A., Owsley, D. W., & Tuross, N. (1999). Identification of Treponema pallidum subspecies pallidum in a 200-year-old skeletal specimen. Journal of Infectious Diseases, 180(6), 2060–2063.
  88. LaMattina, J. L. (2011). The impact of mergers on pharmaceutical R&D. Nature Reviews. Drug Discovery, 10(8), 559.
  89. Lazarus, R. J. (2008). The making of environmental law. University of Chicago Press.
  90. Levin, D. A. (1976). The chemical defenses of plants to pathogens and herbivores. Annual Review of Ecology and Systematics, 7(1), 121–159.
  91. Lewis, J. (1985). The birth of EPA. EPA J., 11, 6.
  92. Liaw, S.-T., & Peterson, G. (2009). Doctor and pharmacist—back to the apothecary! Australian Health Review, 33(2), 268–278.
  93. Linthorst, J. A. (2010). An overview: origins and development of green chemistry. Foundations of Chemistry, 12(1), 55–68.
  94. Lukehart, S. A., Hook, E. W., Baker-Zander, S. A., Collier, A. C., Critchlow, C. W., & Handsfield, H. H. (1988). Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Annals of Internal Medicine, 109(11), 855–862.
  95. Mahlich, J. C. (2010). Patents and performance in the Japanese pharmaceutical industry: An institution-based view. Asia Pacific Journal of Management, 27(1), 99–113.
  96. Mclaughlin, D. (2003). Fooling with Nature, Silent Spring Revisited. PBS, Http://www. Pbs. Org/wgbh/pages/frontline/shows/nature/disrupt/sspring. Html Copyright.
  97. McMurry, J. (2012). Organic Chemistry (8th ed.). Belmont, USA: Brooks/Cole.
  98. McMurry, J., Castellion, M. E., & Ballantine, D. S. (2007). General, Organic and Biological chemestry, 5ed. Pearson; Prentice Hall.
  99. Miller, H. I., & Henderson, D. R. (2007). Governmental influences on drug development: striking a better balance. Nature Reviews. Drug Discovery, 6(7), 532.
  100. Moors, E. H. M., Cohen, A. F., & Schellekens, H. (2014). Towards a sustainable system of drug development. Drug Discovery Today, 19(11), 1711–1720.
  101. Moors, E. H. M., & Faber, J. (2007). Orphan drugs: Unmet societal need for non-profitable privately supplied new products. Research Policy, 36(3), 336–354.
  102. Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D. (2011). The cost of drug development: a systematic review. Health Policy, 100(1), 4–17.
  103. Morphy, R., Kay, C., & Rankovic, Z. (2004). From magic bullets to designed multiple ligands. Drug Discovery Today, 9(15), 641–651.
  104. Munos, B. (2009). Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3, 711–715.
  105. Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews. Drug Discovery, 8(12), 959.
  106. Munos, B. (2010). Can Open‐Source Drug R&D Repower Pharmaceutical Innovation? Clinical Pharmacology & Therapeutics, 87(5), 534–536.
  107. Musselwhite, L. W., & Andrews, J. (2010). Protect Pharmaceutical Innovation. Science, 328(5984), 1354.
  108. Nattrass, N., & Kalichman, S. C. (2009). The politics and psychology of AIDS denialism. In HIV/AIDS in South Africa 25 Years On (pp. 123–134). Springer.
  109. Nicolaou, K. C. (2013). The emergence of the structure of the molecule and the art of its synthesis. Angewandte Chemie International Edition, 52(1), 131–146.
  110. Nicolaou, K. C. (2014). Organic synthesis: the art and science of replicating the molecules of living nature and creating others like them in the laboratory. In Proc. R. Soc. A (Vol. 470, p. 20130690). The Royal Society.
  111. Nicolaou, K. C., & Chen, J. S. (2011). Classics in total synthesis III: further targets, strategies, methods (Vol. 3). John Wiley & Sons.
  112. Nicolaou, K. C., & Montagnon, T. (2008). Molecules that changed the world. Wiley-VCH Weinheim.
  113. Noakes, T. D., Goodwin, N., Rayner, B. L., Branken, T., & Taylor, R. K. (1985). Water intoxication: a possible complication during endurance exercise. Medicine and Science in Sports and Exercise, 17(3), 370–375.
  114. Novac, N. (2013). Challenges and opportunities of drug repositioning. Trends in Pharmacological Sciences, 34(5), 267–272.
  115. Nzila, A., Okombo, J., Becker, R. P., Chilengi, R., Lang, T., & Niehues, T. (2010). Anticancer agents against malaria: time to revisit? Trends in Parasitology, 26(3), 125–129.
  116. O’connell, D. (2007). Neglected diseases. Nature, 449(7159), 157.
  117. Okie, S. (2009). Multinational Medicines--Ensuring Drug Quality in an Era of Global Manufacturing. The New England Journal of Medicine, 361(8), 737.
  118. Olfson, M., & Marcus, S. C. (2013). Decline in placebo-controlled trial results suggests new directions for comparative effectiveness research. Health Affairs, 32(6), 1116–1125.
  119. Oudshoorn, N. (1993). United we stand: the pharmaceutical industry, laboratory, and clinic in the development of sex hormones into scientific drugs, 1920-1940. Science, Technology, & Human Values, 18(1), 5–24.
  120. Ouellette, R. J., & Rawn, J. D. (2015). Principles of organic chemistry (1st ed.). Elsevier.
  121. Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews. Drug Discovery, 10(6), 428.
  122. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews. Drug Discovery, 9(3), 203.
  123. Pauling, L. (1960). The nature of the chemical bond and the structure of molecules and crystals: an introduction to modern structural chemistry (Vol. 18). Cornell University Press.
  124. Paull, J. (2013). The Rachel Carson letters and the making of Silent Spring. Sage Open, 3(3), 2158244013494861.
  125. Peck, C. C., & Cross, J. T. (2007). “ Getting the dose right”: facts, a blueprint, and encouragements. Clinical Pharmacology and Therapeutics, 82(1), 12–14.
  126. Pimentel, D., & Burgess, M. (2014). Environmental and economic costs of the application of pesticides primarily in the United States. In Integrated pest management (pp. 47–71). Springer.
  127. Program, N. T. (1990). NTP Carcinogenesis Studies of Trichloroethylene (Without Epichlorohydrin)(CAS No. 79-01-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Technical Report Series, 243, 1.
  128. Rafols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O’Hare, A., Perianes-Rodríguez, A., & Nightingale, P. (2014). Big pharma, little science?: A bibliometric perspective on Big Pharma’s R&D decline. Technological Forecasting and Social Change, 81, 22–38.
  129. Ratliff, D. (2009). Coroner: water overdose killed HS football player. Accessed December, 16.
  130. Richards, H. (1999). Beyond Silent Spring: Integrated Pest Management and Chemical Safety. Edited by HF van Emden and DB Peakall. Integrated Pest Management Reviews, 4(3), 269–270.
  131. Rowntree, L. G. (1923). Water intoxication. Archives of Internal Medicine, 32(2), 157–174.
  132. Russo, M. J., & Balekdjian, D. (2008). Weighing the outcomes. Nature Biotechnology, 26(2), 173–182.
  133. Schmid, E. F., & Smith, D. A. (2007). Pharmaceutical R&D in the spotlight: why is there still unmet medical need? Drug Discovery Today, 12(23), 998–1006.
  134. Schuhmacher, A., Germann, P.-G., Trill, H., & Gassmann, O. (2013). Models for open innovation in the pharmaceutical industry. Drug Discovery Today, 18(23), 1133–1137.
  135. Sepkowitz, K. A. (2011). One hundred years of Salvarsan. N Engl J Med, 365, 291–293.
  136. Singh, A. E., & Romanowski, B. (1999). Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clinical Microbiology Reviews, 12(2), 187–209.
  137. Sjöström, J., & Talanquer, V. (2014). Humanizing chemistry education: From simple contextualization to multifaceted problematization. Journal of Chemical Education, 91(8), 1125–1131.
  138. Skrbo, A., & Masic, I. (2017). Influence of Arabian Pharmacy on Diseases Tretament During Ottoman’s Period in Bosnia and Herzegovina. Medical Archives, 71(3), 219.
  139. Smith, R. (2005). Curbing the influence of the drug industry: a British view. PLoS Medicine, 2(9), e241.
  140. Solomons, T. W. G., & Fryhle, C. B. (2000). Organic Chemistry (7th ed.). USA: Wiley & Sons.
  141. Solomons, T. W. G., & Fryhle, C. B. (2004). Organic chemistry (8th ed.). USA: Wiley & Sons.
  142. Solomons, T. W. G., & Fryhle, C. B. (2007). Organic Chemistry (9th ed.). USA: Wiley & Sons.
  143. Solomons, T. W. G., & Fryhle, C. B. (2011). Organic Chemistry (10th ed.). USA: Wiley & Sons.
  144. Solomons, T. W. G., Fryhle, C. B., & Snyder, S. A. (2014). Organic chemistry (11th ed.). USA: Wiley & Sons.
  145. Tansey, E. M. (2002). Medicines and men: Burroughs, Wellcome & Co, and the British drug industry before the Second World War. Journal of the Royal Society of Medicine, 95(8), 411–416.
  146. Taylor, R. S., Drummond, M. F., Salkeld, G., & Sullivan, S. D. (2004). Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ: British Medical Journal, 329(7472), 972.
  147. Thomson, C. J., Power, E., Ruebsamen-Waigmann, H., & Labischinski, H. (2004). Antibacterial research and development in the 21 st Century–an industry perspective of the challenges. Current Opinion in Microbiology, 7(5), 445–450.
  148. Tralau-Stewart, C. J., Wyatt, C. A., Kleyn, D. E., & Ayad, A. (2009). Drug discovery: new models for industry–academic partnerships. Drug Discovery Today, 14(1), 95–101.
  149. Vallance, P., Williams, P., & Dollery, C. (2010). The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clinical Pharmacology & Therapeutics, 87(5), 525–527.
  150. Van Emden, H. F., & Peakall, D. B. (1996). Beyond silent spring: integrated pest management and chemical safety. Chapman & Hall Ltd.
  151. Vollhardt, P., & Schore, N. (2014). Organic Chemistry Structure and Function (7th ed.). Freeman.
  152. Wade, L. G. (2009). Organic chemistry (7th ed.). USA: Prentice Hall.
  153. Wade, L. G. (2013). Organic Chemistry (8th ed.). Pearson.
  154. Walsh, C. (2003). Antibiotics: actions, origins, resistance. American Society for Microbiology (ASM).
  155. Winau, F., Westphal, O., & Winau, R. (2004). Paul Ehrlich—in search of the magic bullet. Microbes and Infection, 6(8), 786–789.
  156. Winger, J. (2010). Hydration practices for young athletes questioned. Pediatric Annals, 39(11), 687–688.
  157. Witkop, B. (1999). Paul Ehrlich and his magic bullets, revisited. Proceedings of the American Philosophical Society, 143(4), 540–557.
  158. Wood, A. J. J. (2006). A proposal for radical changes in the drug-approval process. Mass Medical Soc.
  159. Woodcock, J. (2010). Precompetitive research: a new prescription for drug development? Clinical Pharmacology & Therapeutics, 87(5), 521–523.
  160. Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011). Development of novel combination therapies. New England Journal of Medicine, 364(11), 985–987.
  161. Yancey, A., & Stewart Jr, C. N. (2010). Patent reform in the US: what’s at stake for pharmaceutical innovation? Expert Opinion on Therapeutic Patents, 20(5), 603–608.
  162. Zaffiri, L., Gardner, J., & Toledo-Pereyra, L. H. (2012). History of antibiotics. From salvarsan to cephalosporins. Journal of Investigative Surgery, 25(2), 67–77.
  163. Zucker, L. G., & Darby, M. R. (1996). Star scientists and institutional transformation: Patterns of invention and innovation in the formation of the biotechnology industry. Proceedings of the National Academy of Sciences, 93(23), 12709–12716.

No hay comentarios:

Publicar un comentario